文献速递乳腺癌支持与姑息治疗

低剂量他莫昔芬降低乳腺密度:一项随机对照试验

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2021-03-18

KARISMA II期试验纳入1439名40-74岁女性,随机接受安慰剂或1、2.5、5、10、20 mg他莫昔芬6个月。主要终点为乳腺密度下降幅度非劣于20 mg组中位下降10.1%,非劣效界值17%。2.5、5、10 mg组在绝经前女性中非劣效,且严重血管舒缩症状减少约50%。

要点

  • 绝经前女性2.5 mg他莫昔芬降低乳腺密度非劣效于20 mg标准剂量。
  • 2.5、5、10 mg组严重血管舒缩症状较20 mg组减少约50%。
  • 绝经后女性未显示非劣效,密度下降效应限于绝经前女性。

核心结论

  • 绝经前女性2.5 mg他莫昔芬降低乳腺密度的幅度非劣效于20 mg,且副作用更少。

研究设计与样本

  • 6个月双盲六臂随机安慰剂对照非劣效剂量确定II期KARISMA试验,按绝经状态分层。
  • 纳入1439名40-74岁参加瑞典乳腺筛查的女性,1230名可进行意向性分析。

主要发现

  • 2.5、5、10 mg组乳腺密度下降非劣效于20 mg组中位下降10.1%,该效应限于绝经前女性。
  • 2.5、5、10 mg组严重血管舒缩症状(潮热、冷汗、盗汗)较20 mg组减少约50%。

关键数值与推荐

  • 主要终点为乳腺密度下降至少达到20 mg组中位下降10.1%的女性比例,非劣效界值17%。
  • 非劣效仅见于绝经前女性,绝经后女性未显示非劣效。

临床怎么用

  • 绝经前高风险女性可考虑2.5 mg他莫昔芬作为降低乳腺密度的替代剂量,副作用更少。
  • 2.5 mg他莫昔芬是否降低原发性乳腺癌风险尚需未来研究验证。

局限性

  • 研究为6个月II期试验,主要终点为乳腺密度替代指标而非乳腺癌发生率。
  • 非劣效结论仅限于绝经前女性,绝经后女性未显示非劣效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms. PATIENTS AND METHODS: Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis. RESULTS: The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group. CONCLUSION: Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eriksson M, Eklund M, Borgquist S, et al. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. J Clin Oncol. 2021. PMID: 33734864. doi:10.1200/JCO.20.02598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。